Champions Oncology Reports $59.4M Revenue with 4.4% Growth, Faces $1.2M Net Loss

Champions Oncology, Inc. reported a revenue of approximately $59.4 million for the fiscal year ending April 30, 2026, marking a 4.4% increase from the previous year's revenue of $56.9 million. The growth in revenue was primarily driven by an increase in pharmacology services, which rose to $57.1 million from $48.6 million in the prior year. However, the company experienced a net loss of $1.2 million, a significant decline from a net income of $4.7 million in the previous fiscal year. This shift in profitability was attributed to increased operating expenses, which rose by 15.6% to $60.6 million, largely due to higher costs in research and development, sales and marketing, and general administrative expenses.

In terms of operational metrics, Champions Oncology's customer base has expanded, with approximately 500 pharmaceutical and biotechnology companies utilizing its services over the past decade. The company has also focused on enhancing its TumorBank, which now includes around 1,500 Patient Derived Xenograft (PDX) models. This strategic effort aims to improve the predictive capabilities of its oncology research services. The company has invested significantly in research and development, with expenses increasing by 33.1% to $9.1 million, reflecting its commitment to advancing its technology platforms and expanding its data offerings.

Champions Oncology has also made notable changes in its organizational structure and strategic focus. The company has shifted its emphasis away from flow cytometry services, which contributed to a decrease in other TOS revenue. Additionally, the company has been actively expanding its data licensing customer base, although it did not replicate a significant data license transaction from the previous year. The company’s employee headcount stood at 214 as of July 15, 2026, with a substantial portion engaged in research and development activities.

Looking ahead, Champions Oncology aims to leverage its technology platforms to drive multiple revenue streams and establish a global leadership position in oncology research. The company plans to continue investing in its TumorBank and enhance its experimental technologies to support drug discovery and development. Despite the current financial challenges, management believes that its cash reserves, along with expected cash flows from operations, will be sufficient to fund operations through at least August 2027. However, the company acknowledges the need for potential capital raises to support its growth initiatives.